				<del></del>	<del></del>	TA A . A A B			
Form PTO-1449 Substitute			■		Application Number	<del></del>			
			Patent and Tr	ademark Office	Filing Date	January 4, 20			
						David Baltimo	ore		
/ 0	. `	ION DISCLOST		ENT	Art Unit	1636			
Wse sev	era)	sheets if necessar	r <b>y</b> )		Examiner Name	Trees. Hibl	pert		
1	200	3			Attorney Docket No.	75723-	_		
FEB 08	Jona	<del>- 8)</del>			<u> </u>	ZA/JPW/GJG/C	<u> </u>		
32		<i>E/</i>	NON PATENT	LITERATURE DOC	TIMENTS				
EXMINER		Include name of the			<del>- ·</del>	rigte), title of the item	T <sup>2</sup>		
Initials	No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
/C.H./	1	Response to October 16, 2008 Final Office Action, Summary of December 2, 2008 Examiner Interview, and Statement of Concurrent Proceedings Under 37 C.F.R. § 1.565, filed January 26, 2009 in Merged Reexamination Control Nos. 90/007,503 and 90/007,828;							
/C.H./	2	Third Declaration of Dr. Inder Verma, dated January 26, 2009;							
/C.H./	3	Final Office Action issued October 16, 2008 in Merged Reexamination Control Nos. 90/007,503 and 90/007,828;							
/C.H./	4	Brief for Appellants, ARIAD, filed December 16, 2008 in the concurrent litigation captioned Amgen Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al., U.S. Court of Appeals for the Federal Circuit, Docket No. 2009-1023;							
				on Chart, fil					
	5	litigation captioned Amgen Inc., et al. v. ARIAD  Pharmaceuticals, Inc., et al., U.S. District Court for the  District of Delaware, CA No. 06-259(MPT);							
		Deposition Transcript of Randolph Wall, Ph.D., pages 149- 152. in the concurrent litigation captioned Amgen Inc. et							
	6	al. v. ARIAD Pharmaceuticals, Inc., et al., U.S. District Court for the District of Delaware, CA No. 06-259(MPT);							
/C.H./	7	ARIAD's Reply in Support of Motion to Strike Extra-Record Materials From the Joint Appendix, filed January 21, 2009 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of Appeals for the Federal Circuit, Docket No. 2008-1248;							
EXAMINEI SIGNATUR		/Catherine Hibl	pert/	DATE CONSIDERED	04/08/2009				

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Applicants: David Baltimore, et al. Serial No.: 10/037,341 Filed: January 4, 2002

C.H.   C.H.   C.H.   C.H.   C.H.   C.H.	Form D	FO 1	440 Substituto	IIC Donortes	ant of Commono	Application Number	110/027 241							
Inc.   Cit.   Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (hook, magezine, journal, serial, symposium, catalog, etc.) date, pages, volume-issue numbers), publisher, city and company, u. S. Court of Appeals for the Federal Circuit, Docket No. 2008-1248;    C.H.	rorm P	10-1	449 Substitute	_			10/037,341	202						
Information disclosure statement   Information   Informa				ratent and 1	rademark Office									
Examiner Name   Total processory   Examiner Name   Total process   Total pro	INEOD	мат	TON DISCLOSI	DE STATEM	ENT		<del></del>	JI C						
NON PATENT LITERATURE DOCUMENTS  Examiner Cite Initials    College		. — — —			ert									
C.H.   C.H.	(Use sev	erai	sneets ii necessar											
NON PATENT LITERATURE DOCUMENTS  Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item foods, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, dity and/or country where published.    C.H.						Attorney Docket No.		5						
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magadne, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, dry ann/or country where published.    C.H.														
Initials No. (book, magazine, journal, serial, symposium, catalog, etc.) date, pagets), volume-issue number(s), publisher, divandor country where published.  Lilly's Opposition to ARIAD's Motion to Strike Materials From the Joint Appendix, filed January 9, 2009 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of Appeals for the Federal Circuit, Docket No. 2008-1248;  Motion of Plaintiffs-Appellees, ARIAD, to Strike Extra-Record Materials From the Joint Appendix, filed December 23, 2008 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of Appeals for the Federal Circuit, Docket No. 2008-1248;  Reply Brief on Defendant-Appellant Eli Lilly and Company, filed November 12, 2008 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of Appeals for the Federal Circuit, Docket No. 2008-1248;  Questions to the Jury on Special Verdict, dated April 28, 2006, in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly & Co., U.S. District Court for the District of Massachusetts, CA No. 02-CV-11280-RWZ; and  Defendant Eli Lilly and Company's Motion in Limine to Exclude Adding Claim Limitations and Expert Testimony That Offers Construction of Claim Terms Inconsistent With the Court's Construction of Claim Terms Inconsistent With the Court for the District of Massachusetts, CA No. 02-CV-11280-RWZ.		r — —	<u> </u>											
C.H.   8   From the Joint Appendix, filed January 9, 2009 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of Appeals for the Federal Circuit, Docket No. 2008-1248;			lo. (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city											
Record Materials From the Joint Appendix, filed December 23, 2008 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of Appeals for the Federal Circuit, Docket No. 2008-1248;  Reply Brief on Defendant-Appellant Eli Lilly and Company, filed November 12, 2008 in the concurrent litigation 10 captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of Appeals for the Federal Circuit, Docket No. 2008-1248;  Questions to the Jury on Special Verdict, dated April 28, 2006, in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly & Co., U.S. District Court for the District of Massachusetts, CA No. 02-CV-11280-RWZ; and  Defendant Eli Lilly and Company's Motion in Limine to Exclude Adding Claim Limitations and Expert Testimony That offers Construction of Claim Terms Inconsistent With the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly & Co., U.S. District Court for the District of Massachusetts, CA No. 02-CV-11280-RWZ.	/C.H./		From the Joint Appendix, filed January 9, 2009 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of											
filed November 12, 2008 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of Appeals for the Federal Circuit, Docket No. 2008-1248;  Questions to the Jury on Special Verdict, dated April 28, 2006, in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly & Co., U.S. District Court for the District of Massachusetts, CA No. 02-CV-11280-RWZ; and  Defendant Eli Lilly and Company's Motion in Limine to Exclude Adding Claim Limitations and Expert Testimony That Offers Construction of Claim Terms Inconsistent With the Court's Construction, filed February 24, 2006 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly & Co., U.S. District Court for the District of Massachusetts, CA No. 02-CV-11280-RWZ.	/C.H./	ŧ	Record Materials From the Joint Appendix, filed December 23, 2008 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of Appeals for the Federal Circuit, Docket No.											
2006, in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly & Co., U.S. District Court for the District of Massachusetts, CA No. 02-CV-11280-RWZ; and  Defendant Eli Lilly and Company's Motion in Limine to Exclude Adding Claim Limitations and Expert Testimony That Offers Construction of Claim Terms Inconsistent With the Court's Construction, filed February 24, 2006 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly & Co., U.S. District Court for the District of Massachusetts, CA No. 02-CV-11280-RWZ.	/C.H./	10	filed November 12, 2008 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of Appeals for the Federal Circuit,											
C.H./  Exclude Adding Claim Limitations and Expert Testimony That Offers Construction of Claim Terms Inconsistent With the Court's Construction, filed February 24, 2006 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly & Co., U.S. District Court for the District of Massachusetts, CA No. 02-CV-11280-RWZ.  EXAMINER (Cothorine Hibbort)  OM/08/2000	/C.H./	11	2006, in the concurrent litigation captioned ARIAD  Pharmaceuticals, Inc., et al. v. Eli Lilly & Co., U.S.  District Court for the District of Massachusetts, CA No.											
	/C.H./	!	Exclude Adding Claim Limitations and Expert Testimony That Offers Construction of Claim Terms Inconsistent With the Court's Construction, filed February 24, 2006 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly & Co., U.S. District Court for											
			/Catherine Hibbe	rt/	DATE CONSIDERED	04/08/2009	•							

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.